• Species Reactivity

  Human

• Specificity

  Detects human TINAGL1 in direct ELISAs and Western blots. In Western blots, no cross-reactivity with recombinant human TIN-Ag is observed.    
   

• Source

  Monoclonal Mouse IgG    ₁ Clone # 812417

• Purification

  Protein A or G purified from hybridoma culture supernatant

• Immunogen

  Chinese hamster ovary cell line CHO-derived recombinant human TINAGL1    
  Ala22-Met464    
  Accession # Q9GZM7

• Formulation

  Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS.

• Label

  Unconjugated

Applications

• Recommended    
  Concentration

  Sample

• Western Blot

  0.5 μg/mL

  See below

• 
  

• Simple Western

  5 μg/mL

  See below

• 
  

Please Note: Optimal dilutions should be determined by each laboratory for each application.  are available in the Technical Information section on our website.

Data Examples

Preparation and Storage

• Reconstitution

  Sterile PBS to a final concentration of 0.5 mg/mL.

• Shipping

  The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

• Stability & Storage

  Use a manual defrost freezer and avoid repeated freeze-thaw cycles.    

• 12 months from date of receipt, -20 to -70 °C as supplied.

• 1 month, 2 to 8 °C under sterile conditions after reconstitution.

• 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: TINAGL1

TINAGL1 (Tubulointerstitial nephritis antigen-like 1; also TIN-ag-RP, AZ-1 and LCN7) is a 54-57 kDa glycoprotein member of the peptidase C1 family of molecules. It is secreted by renal tubule epithelium, zona glomerulosa cells, vascular smooth muscle and striated muscle cells. TINAGL1 may play a role in the spatial and temporal development of the steroid component of the adrenal, in part by suppressing the expression of CYP11B1. Human TINAGL1 is synthesized as a 467 amino acid (aa) precursor. It contains a 21 aa signal sequence and a 446 aa mature region (aa 22-467). Within the mature region is an SMB (somatomedin B) domain (aa 50-98), one vWFC domain (aa 105-140), and a nonenzymatic peptidase C1A region (aa 204-455). There are multiple potential isoform variants. One contains an alternative start site at Met106, another shows a deletion of aa 126-156, and a third possesses a 60 aa substitution for aa 1-194, coupled to a 38 aa insertion after Gly286, and a 16 aa substitution for aa 365-467. Undefined forms of 40-42 kDa and 22 kDa  have been noted in TINAGL1-transfected cell supernatant subjected to SDS-PAGE. Over aa 22?464, human TINAGL1 shares 90% aa identity with mouse TINAGL1.

• Long Name:

  Tubulointerstitial Nephritis Antigen-like 1

• Entrez Gene IDs:

  64129 (Human); 94242 (Mouse); 94174 (Rat)

• Alternate Names:

  androgen-regulated gene 1; ARG1; GIS5; Glucocorticoid-inducible protein 5; LCN7; LIECG3; lipocalin 7; OLRG2; OLRG-2; Oxidized LDL-responsive gene 2 protein; oxidized-LDL responsive gene 2; P3ECSL; TIN Ag-related protein; TINAGL; TINAGL1; TINAG-like 1; TINAGRP; TIN-ag-RP; tubulointerstitial nephritis antigen-like 1; tubulointerstitial nephritis antigen-like; Tubulointerstitial nephritis antigen-related protein